News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEvents
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Kelly Filchner, PhD, MSN, RN, OCN, CCRC

Advertisement

Articles by Kelly Filchner, PhD, MSN, RN, OCN, CCRC

medical terminology

Are You Speaking the Same Language When Discussing Biomarkers With Your Patients?

ByKelly Filchner, PhD, MSN, RN, OCN, CCRC
April 21st 2023

Oncology Nurses: Have You Read a Good Book Lately?

ByKelly Filchner, PhD, MSN, RN, OCN, CCRC
May 6th 2019

“In hindsight, I understood the science behind why the trials were being conducted, but probably did not appreciate their history.”

Advertisement

Latest Updated Articles

  • Oncology Nurses: Have You Read a Good Book Lately?
    Oncology Nurses: Have You Read a Good Book Lately?

    Published: May 6th 2019 | Updated:



Advertisement
Advertisement

Trending on Oncology Nursing News

1

FDA Greenlights Niraparib/Abiraterone Acetate With Prednisone in mHSPC

2

Oral Azacitidine Yields Similar PK to Subcutaneous Azacitidine in MDS/CMML

3

Frontline Axi-Cel CR Linked With Improved Survival in High-Risk LBCL

4

Sacituzumab Govitecan Fails to Reach Significant PFS in HR+/HER2– mBC

5

Progression Occurs Early in R/R LBCL Treated With Epcoritamab, Glofitamab

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us